STRO Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 108078 min ago

@ $4.45

Ausgestellt: 14 Feb 2024 @ 19:11

Rendite: -20.35%

Vorheriges Signal: Feb 14 - 15:30

Vorheriges Signal: Verkaufen

Rendite: -4.28 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:28):

Stats
Tagesvolumen	394 556
Durchschnittsvolumen	999 409
Marktkapitalisierung	272.68M
EPS	$0 ( 2024-04-04 )
Nächstes Ertragsdatum	( $-0.910 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.990
ATR14	$0.00700 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Srinivasan Venkatesh	Sell	21 250	Restricted Stock Unit (RSU)
2024-04-11	Srinivasan Venkatesh	Buy	21 250	Common Stock
2024-04-11	Srinivasan Venkatesh	Sell	7 582	Common Stock
2024-03-05	Newell William J	Buy	167 000	Restricted Stock Units (RSUs)
2024-03-05	Fitzpatrick Linda A	Buy	37 100	Restricted Stock Units (RSUs)

INSIDER POWER
67.78
Last 99 transactions
Buy: 2 171 384 \| Sell: 404 320

Volumen Korrelation

Lang: -0.03 (neutral)

Kurz: 0.52 (weak)

Signal:(47.711) Neutral

Sutro Biopharma Inc Korrelation

10 Am meisten positiv korreliert
TNGX	0.88
CARA	0.864
EYE	0.821
SLM	0.809
ACHC	0.801
LSXMK	0.801

10 Am meisten negativ korreliert
ALR	-0.839
INZY	-0.833
BTBD	-0.83
INOD	-0.828
GETVV	-0.826
HYPR	-0.824
FTIV	-0.812
OCUL	-0.803
SELF	-0.802

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Sutro Biopharma Inc Korrelation - Währung/Rohstoff

-0.16
( neutral )

0.25
( neutral )

0.00
( neutral )

0.40
( neutral )

0.78
( moderate )

-0.04
( neutral )

Sutro Biopharma Inc Finanzdaten

Annual	2023
Umsatz:	$153.73M
Bruttogewinn:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2023
Umsatz:	$153.73M
Bruttogewinn:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2022
Umsatz:	$67.77M
Bruttogewinn:	$59.48M (87.77 %)
EPS:	$-2.35

FY	2021
Umsatz:	$61.88M
Bruttogewinn:	$61.88M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.